Signal transduction in the erythropoietin receptor system

Experimental Cell Research

Volumn 253, Issue 1, 1999, Pages 143-156

  Wojchowski, Don M ^a   Gregory, Richard C ^a   Miller, Chris P ^a   Pandit, Ajay K ^a   Pircher, Tony J ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Epo; Epo receptor; Erythropoiesis; Erythropoietin

Indexed keywords

ADAPTOR PROTEIN; CYTOKINE RECEPTOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; INTERLEUKIN 3 RECEPTOR;

APOPTOSIS; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; ERYTHROPOIESIS; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033604519     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4673     Document Type: Article

References (197)

1. D'Andrea A. D., Lodish H. F., Wong G. G. Expression cloning of the murine erythropoietin receptor. Cell. 57:1989;277-285.
2. Jones S. S., D'Andrea A. D., Haines L. L., Wong G. G. Human erythropoietin receptor: Cloning, expression, and biologic characterization. Blood. 76:1990;31-35.
3. Bazan J. F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA. 87:1990;6934-6938.
4. Livnah O., Stura E. A., Johnson D. L., Middleton S. A., Mulcahy L. S., Wrighton N. C., Dower W. J., Jolliffe L. K., Wilson I. A. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 A. Science. 273:1996;464-471.
5. Syed R. S., Reid S. W., Li C., Cheetham J. C., Aoki K. H., Liu B., Zhan H., Osslund T. D., Chirino A. J., Zhang J., Finer-Moore J., Elliott S., Sitney K., Katz B. A., Matthews D. J., Wendoloski J. J., Egrie J., Stroud R. M. Efficiency of signaling through cytokine receptors depends critically on receptor orientation. Nature. 395:1998;511-516.
6. Bork P., Holm L., Sander C. The immunoglobulin fold. Structural classification, sequence patterns and common core. J. Mol. Biol. 242:1994;309-320.
7. Quelle D. E., Quelle F. W., Wojchowski D. M. Mutations in the WSAWSE and cytosolic domains of the erythropoietin receptor affect signal transduction and ligand binding and internalization. Mol. Cell. Biol. 12:1992;4553-4561.
8. Zhuang H., Patel S. V., He T. C., Sonsteby S. K., Niu Z., Wojchowski D. M. Inhibition of erythropoietin-induced mitogenesis by a kinase-deficient form of Jak2. J. Biol. Chem. 269:1994;21411-21414.
9. Jiang N., He T. C., Miyajima A., Wojchowski D. M. The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimera. J. Biol. Chem. 271:1996;16472-16476.
10. Ihle J. N. Cytokine receptor signaling. Nature. 377:1995;591-594.
11. Tortolani P. J., Johnston J. A., Bacon C. M., McVicar D. W., Shimosaka A., Linnekin D., Longo D. L., O'Shea J. J. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood. 85:1995;3444-3451.
12. Rui H., Kirken R. A., Farrar W. L. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J. Biol. Chem. 269:1994;5364-5368.
13. Argetsinger L. S., Campbell G. S., Yang X., Witthuhn B. A., Silvennoinen O., Ihle J. N., Carter-Su C. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 74:1993;237-244.
14. Witthuhn B. A., Quelle F. W., Silvennoinen O., Yi T., Tang B., Miura O., Ihle J. N. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 74:1993;227-236.
15. Bacon C. M., Tortolani P. J., Shimosaka A., Rees R. C., Longo D. L., O'Shea J. J. Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett. 370:1995;63-68.
16. Gouilleux F., Wakao H., Mundt M., Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J. 13:1994;4361-4369.
17. Wood T. J. J., Sliva D., Lobie P. E., Pircher T. J., Gouilleux F., Wakao H., Gustafsson J. A., Groner B., Norstedt G., Haldosen L. A. Mediation of growth hormone-dependent transcriptional activation by mammary gland factor/Stat 5. J. Biol. Chem. 270:1995;9448-9453.
18. Gouilleux F., Pallard C., Dusanter-Fourt I., Wakao H., Haldosen L. A., Norstedt G., Levy D., Groner B. Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J. 14:1995;2005-2013.
19. Reese T. T., Gregory R. C., Sharlow E. R., Pacifici R. E., Crouse J. A., Todokoro K., Wojchowski D. M. Epo-induced hemoglobinization of SKT6 cells is mediated by minimal cytoplasmic domains of the Epo or prolactin receptors without modulation of GATA-1 or EKLF. Growth Factors. 14:1997;161-176.
20. Goldsmith M. A., Mikami A., You Y., Liu K. D., Thomas L., Pharr P., Longmore G. D. Absence of cytokine receptor-dependent specificity in red blood cell differentiation in vivo. Proc. Natl. Acad. Sci. USA. 95:1998;7006-7011.
21. Kieran M. W., Perkins A. C., Orkin S. H., Zon L. I. Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc. Natl. Acad. Sci. USA. 93:1996;9126-9131.
22. Socolovsky M., Fallon A. E., Lodish H. F. The prolactin receptor rescues EpoR-/- erythroid progenitors and replaces EpoR in a synergistic interaction with c-kit. Blood. 92:1998;1491-1496.
23. Wu H., Liu X., Jaenisch R., Lodish H. F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 83:1995;59-67.
24. Lin C. S., Lim S. K., D'Agati V., Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 10:1996;154-164.
25. Okada A., Kinoshita Y., Maekawa T., Hassan M. S., Kawanami C., Asahara M., Matsushima Y., Kishi K., Nakata H., Naribayashi Y., Chiba T. Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells. Digestion. 57:1996;328-332.
26. Ammarguellat F., Gogusev J., Drueke T. B. Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol. Dial. Transplant. 11:1996;687-692.
27. Koshimura K., Murakami Y., Sohmiya M., Tanaka J., Kato Y. Effects of erythropoietin on neuronal activity. J. Neurochem. 72:1999;2565-2572.
28. Bernaudin M., Marti H. H., Roussel S., Divoux D., Nouvelot A., MacKenzie E. T., Petit E. A. Potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 19:1999;643-651.
29. Sadamoto Y., Igase K., Sakanaka M., Sato K., Otsuka H., Sakaki S., Masuda S., Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem. Biophys. Res. Commun. 253:1998;26-32.
30. Koury M. J., Bondurant M. C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 248:1990;378-381.
31. Socolovsky M., Fallon A. E., Wang S., Brugnara C., Lodish H. F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: A direct role for Stat5 in Bcl-X(L) induction. Cell. 98:1999;181-191.
32. Kelley L. L., Green W. F., Hicks G. G., Bondurant M. C., Koury M. J., Ruley H. E. Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol. Cell. Biol. 14:1994;4183-4192.
33. Dessypris E. N., Krantz S. B. Effect of pure erythropoietin on DNA-synthesis by human marrow day 15 erythroid burst forming units in short-term liquid culture. Br. J. Haematol. 56:1984;295-306.
34. Miller C. M., Liu Z. Y., Noguchi C., Wojchowski D. M. A minimal cytoplasmic subdomain of the erythropoietin receptor mediates erythroid and megakaryocytic cell development. Blood. 1999.
35. Damen J. E., Cutler R. L., Jiao H., Yi T., Krystal G. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J. Biol. Chem. 270:1995;23402-23408.
36. Sui X., Krantz S. B., You M., Zhao Z. Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood. 92:1998;1142-1149.
37. Bittorf T., Jaster R., Brock J. Rapid activation of the MAP kinase pathway in hematopoietic cells by erythropoietin, granulocyte-macrophage colony-stimulating factor and interleukin-3. Cell Signal. 6:1994;305-311.
38. Umemura T., Umene K., Takahira H., Takeichi N., Katsuno M., Fukumaki Y., Nishimura J., Sakaki Y., Ibayashi H. Hematopoietic growth factors (BPA and Epo) induce the expressions of c-myc and c-fos proto-oncogenes in normal human erythroid progenitors. Leuk. Res. 12:1988;187-194.
39. Lacronique V., Varlet P., Mayeux P., Porteu A., Gisselbrecht S., Kahn A., Lacombe C. Bcl-2 targeted overexpression into the erythroid lineage of transgenic mice delays but does not prevent the apoptosis of erythropoietin-deprived erythroid progenitors. Blood. 90:1997;3050-3056.
40. Chida D., Miura O., Yoshimura A., Miyajima A. Role of cytokine signaling molecules in erythroid differentiation of mouse fetal liver hematopoietic cells: Functional analysis of signaling molecules by retrovirus-mediated expression. Blood. 93:1999;1567-1578.
41. Akashi K., Kondo M., von Freeden-Jeffry U., Murray R., Weissman I. L. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell. 89:1997;1033-1041.
42. Maraskovsky E., O'Reilly L. A., Teepe M., Corcoran L. M., Peschon J. J., Strasser A. Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1-/- mice. Cell. 89:1997;1011-1019.
43. Todokoro K., Kanazawa S., Amanuma H., Ikawa Y. Specific binding of erythropoietin to its receptor on responsive mouse erythroleukemia cells. Proc. Natl. Acad. Sci. USA. 84:1987;4126-4130.
44. Klinken S. P., Nicola N. A., Johnson G. R. In vitro-derived leukemic erythroid cell lines induced by a raf- and myc-containing retrovirus differentiate in response to erythropoietin. Proc. Natl. Acad. Sci. USA. 85:1988;8506-8510.
45. Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K., Piao Y. F., Miyazono K., Urabe A., Takaku F. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140:1989;323-334.
46. O'Prey J., Leslie N., Itoh K., Ostertag W., Bartholomew C., Harrison P. R. Both stroma and stem cell factor maintain long-term growth of ELM erythroleukemia cells, but only stroma prevents erythroid differentiation in response to erythropoietin and interleukin-3. Blood. 91:1998;1548-1555.
47. Elliott S., Lorenzini T., Yanagihara D., Chang D., Elliott G. Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J. Biol. Chem. 271:1996;24691-24697.
48. Schneider H., Chaovapong W., Matthews D. J., Karkaria C., Cass R. T., Zhan H., Boyle M., Lorenzini T., Elliott S. G., Giebel L. B. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood. 89:1997;473-482.
49. Yoshimura A., Longmore G., Lodish H. F. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature. 348:1990;647-649.
50. Socolovsky M., Dusanter-Fourt I., Lodish H. F. The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors. J. Biol. Chem. 272:1997;14009-14012.
51. Dusanter-Fourt I., Muller O., Ziemiecki A., Mayeux P., Drucker B., Djiane J., Wilks A., Harpur A. G., Fischer S., Gisselbrecht S. Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells. EMBO J. 13:1994;2583-2591.
52. Pless M., Norga K., Carroll M., Heim M. H., D'Andrea A. D., Mathey-Prevot B. Receptors that induce erythroid differentiation of Ba/F3 cells: Structural requirements and effect on STAT5 binding. Blood. 89:1997;3175-3185.
53. Pacifici R. E., Thomason A. R. Hybrid tyrosine kinase/cytokine receptors transmit mitogenic signals in response to ligand. J. Biol. Chem. 269:1994;1571-1574.
54. Sharlow E. R., Pacifici R., Crouse J., Batac J., Todokoro K., Wojchowski D. M. Hematopoietic cell phosphatase negatively regulates erythropoietin-induced hemoglobinization in erythroleukemic SKT6 cells. Blood. 90:1997;2175-2187.
55. Gregory R. C., Jiang N., Todokoro K., Crouse J., Pacifici R. E., Wojchowski D. M. Erythropoietin receptor and STAT5-specific pathways promote SKT6 cell hemoglobinization. Blood. 92:1998;1104-1118.
56. Wakao H., Chida D., Damen J. E., Krystal G., Miyajima A. A possible involvement of Stat5 in erythropoietin-induced hemoglobin synthesis. Biochem. Biophys. Res. Commun. 234:1997;198-205.
57. Remy I., Wilson I. A., Michnick S. W. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 283:1999;990-993.
58. Chen M., Cheng A., Chen Y. Q., Hymel A., Hanson E. P., Kimmel L., Minami Y., Taniguchi T., Changelian P. S., O'Shea J. J. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc. Natl. Acad. Sci. USA. 94:1997;6910-6915.
59. Feng J., Witthuhn B. A., Matsuda T., Kohlhuber F., Kerr I. M., Ihle J. N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17:1997;2497-2501.
60. Frank S. J., Yi W., Zhao Y., Goldsmith J. F., Gilliland G., Jiang J., Sakai I., Kraft A. S. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J. Biol. Chem. 270:1995;14776-14785.
61. Luo H., Rose P., Barber D., Hanratty W. P., Lee S., Roberts T. M., D'Andrea A. D., Dearolf C. R. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell. Biol. 17:1997;1562-1571.
62. Neubauer H., Cumano A., Muller M., Wu H., Huffstadt U., Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 93:1998;397-409.
63. Parganas E., Wang D., Stravopodis D., Topham D. J., Marine J. C., Teglund S., Vanin E. F., Bodner S., Colamonici O. R., van Deursen J. M., Grosveld G., Ihle J. N. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 93:1998;385-395.
64. Hou X. S., Melnick M. B., Perrimon N. Marelle acts downstream of the Drosophila HOP/JAK kinase and encodes a protein similar to the mammalian STATs. Cell. 84:1996;411-419.
65. McKendry R., John J., Flavell D., Muller M., Kerr I. M., Stark G. R. High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. Proc. Natl. Acad. Sci. USA. 88:1991;11455-11459.
66. Quelle F. W., Wang D., Nosaka T., Thierfelder W. E., Stravopodis D., Weinstein Y., Ihle J. N. Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol. Cell. Biol. 16:1996;1622-1631.
67. Damen J. E., Wakao H., Miyajima A., Krosl J., Humphries R. K., Cutler R. L., Krystal G. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J. 14:1995;5557-5568.
68. Klingmuller U., Bergelson S., Hsiao J. G., Lodish H. F. Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc. Natl. Acad. Sci. USA. 93:1996;8324-8328.
69. Gobert S., Chretien S., Gouilleux F., Muller O., Pallard C., Dusanter-Fourt I., Groner B., Lacombe C., Gisselbrecht S., Mayeux P. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. EMBO J. 15:1996;2434-2441.
70. Verdier F., Rabionet R., Gouilleux F., Beisenherz-Huss C., Varlet P., Muller O., Mayeux P., Lacombe C., Gisselbrecht S., Chretien S. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: A distinct biochemical difference between STAT5A and STAT5B. Mol. Cell. Biol. 18:1998;5852-5860.
71. Mui A. L., Wakao H., Kinoshita T., Kitamura T., Miyajima A. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: Role of Stat5 in proliferation. EMBO J. 15:1996;2425-2433.
72. Ofir R., Qing W., Krup M., Weinstein Y. Identification of genes induced by interleukin-3 and erythropoietin via the Jak-Stat5 pathway using enhanced differential display-reverse Southern. J. Interferon Cytokine Res. 17:1997;279-286.
73. Matsumura I., Kitamura T., Wakao H., Tanaka H., Hashimoto K., Albanese C., Downward J., Pestell R. G., Kanakura Y. Transcriptional regulation of the cyclin D1 promoter by STAT5: Its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 18:1999;1367-1377.
74. Yoshimura A. The CIS family: Negative regulators of JAK-STAT signaling. Cytokine Growth Factor Rev. 9:1998;197-204.
75. Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I., Sasaki M., Johnston J. A., Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells. 4:1999;339-351.
76. Yoshimura A., Ohkubo T., Kiguchi T., Jenkins N. A., Gilbert D. J., Copeland N. G., Hara T., Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:1995;2816-2826.
77. Matsumoto A., Masuhara M., Mitsui K., Yokouchi M., Ohtsubo M., Misawa H., Miyajima A., Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 89:1997;3148-3154.
78. Schluter G., Celik A., Obata R., Schlicker M., Hofferbert S., Schlung A., Adham I. M., Engel W. Sequence analysis of the conserved protamine gene cluster shows that it contains a fourth expressed gene. Mol. Reprod. Dev. 43:1996;1-6.
79. Verdier F., Chretien S., Muller O., Varlet P., Yoshimura A., Gisselbrecht S., Lacombe C., Mayeux P. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. J. Biol. Chem. 273:1998;28185-28190.
80. Matsumoto A., Seki Y., Kubo M., Ohtsuka S., Suzuki A., Hayashi I., Tsuji K., Nakahata T., Okabe M., Yamada S., Yoshimura A. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol. Cell. Biol. 19:1999;6396-6407.
81. Udy G. B., Towers R. P., Snell R. G., Wilkins R. J., Park S. H., Ram P. A., Waxman D. J., Davey H. W. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. USA. 94:1997;7239-7244.
82. Liu X., Robinson G. W., Wagner K. U., Garrett L., Wynshaw-Boris A., Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11:1997;179-186.
83. Feldman G. M., Rosenthal L. A., Liu X., Hayes. M. P., Wynshaw-Boris A., Leonard W. J., Hennighausen L., Finbloom D. S. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood. 90:1997;1768-1776.
84. Teglund S., McKay C., Schuetz E., van Deursen J. M., Stravopodis D., Wang D., Brown M., Bodner S., Grosveld G., Ihle J. N. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:1998;841-850.
85. Starr R., Willson T. A., Viney E. M., Murray L. J., Rayner J. R., Jenkins B. J., Gonda T. J., Alexander W. S., Metcalf D., Nicola N. A., Hilton D. J. A family of cytokine-inducible inhibitors of signaling. Nature. 387:1997;917-921.
86. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., Ohtsuka S., Imaizumi T., Matsuda T., Ihle J. N., Yoshimura A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1999;1309-1320.
87. Metcalf D., Alexander W. S., Elefanty A. G., Nicola N. A., Hilton D. J., Starr R., Mifsud S., Di Rago L. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia. 13:1999;926-934.
88. De Sepulveda P., Okkenhaug K., Rose J. L., Hawley R. G., Dubreuil P., Rottapel R. Socs1 binds to multiple signaling proteins and suppresses steel factor-dependent proliferation. EMBO J. 18:1999;904-915.
89. Miura O., Miura Y., Nakamura N., Quelle F. W., Witthuhn B. A., Ihle J. N., Aoki N. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlate with Jak2-mediated growth signaling from the erythropoietin receptor. Blood. 84:1994;4135-4141.
90. Lilly M., Le T., Holland P., Hendrickson S. L. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene. 7:1992;727-732.
91. Joneja B., Chen H. C., Seshasayee D., Wrentmore A. L., Wojchowski D. M. Mechanisms of stem cell factor and erythropoietin proliferative co-signaling in FDC2-ER cells. Blood. 90:1997;3533-3545.
92. Breuer M., Wientjens E., Verbeek S., Slebos R., Berns A. Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: Dose dependence and involvement of myc and ras. Cancer Res. 51:1991;958-963.
93. Cuypers H. T., Selten G., Quint W., Zijlstra M., Maandag E. R., Boelens W., van Wezenbeek P., Melief C., Berns A. Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region. Cell. 37:1984;141-155.
94. Mochizuki T., Kitanaka C., Noguchi K., Sugiyama A., Kagaya S., Chi S., Asai A., Kuchino Y. Pim-1 kinase stimulates c-Myc-mediated death signaling upstream of caspase-3 (CPP32)-like protease activation. Oncogene. 15:1997;1471-1480.
95. Mochizuki T., Kitanaka C., Noguchi K., Muramatsu T., Asai A., Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J. Biol. Chem. 274:1999;18659-18666.
96. Leverson J. D., Koskinen P. J., Orrico F. C., Rainio E. M., Jalkanen K. J., Dash A. B., Eisenman R. N., Ness S. A. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol. Cell. 2:1998;417-425.
97. Wojchowski D. M., Joneja B., Pelech S. Pim1 inhibits cell death: Induction of Pim1 and Pim2 transcription via a minimal Epo receptor form, and modulation of apoptosis upon the deregulated expression of Pim1. American Society of Hematology, Thirty-Ninth Annual Meeting, San Diego, CA. Blood. 90:1997.
98. Lilly M., Kraft A. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 57:1997;5348-5355.
99. Chin H., Arai A., Wakao H., Kamiyama R., Miyasaka N., Miura O. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood. 91:1998;3734-3745.
100. Duprez V., Blank U., Chretien S., Gisselbrecht S., Mayeux P. Physical and functional interaction between p72(syk) and erythropoietin receptor. J. Biol. Chem. 273:1998;33985-33990.
101. Machide M., Mano H., Todokoro K. Interleukin 3 and erythropoietin induce association of Vav with Tec kinase through Tec homology domain. Oncogene. 11:1995;619-625.
102. Klingmuller U., Lorenz U., Cantley L. C., Neel B. G., Lodish H. F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 80:1995;729-738.
103. Yi T., Zhang J., Miura O., Ihle J. N. Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: Identification of potential binding sites. Blood. 85:1995;87-95.
104. Tauchi T., Damen J. E., Toyama K., Feng G. S., Broxmeyer H. E., Krystal G. Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis. Blood. 87:1996;4495-4501.
105. Ren H. Y., Komatsu N., Shimizu R., Okada K., Miura Y. Erythropoietin induces tyrosine phosphorylation and activation of phospholipase C-gamma 1 in a human erythropoietin-dependent cell line. J. Biol. Chem. 269:1994;19633-19638.
106. Damen J. E., Liu L., Cutler R. L., Krystal G. Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein. Blood. 82:1993;2296-2303.
107. Cutler R. L., Liu L., Damen J. E., Krystal G. Multiple cytokines induce the tyrosine phosphorylation of Shc and its association with Grb2 in hemopoietic cells. J. Biol. Chem. 268:1993;21463-21465.
108. Odai H., Sasaki K., Iwamatsu A., Hanazono Y., Tanaka T., Mitani K., Yazaki Y., Hirai H. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells. J. Biol. Chem. 270:1995;10800-10805.
109. Barber D. L., Mason J. M., Fukazawa T., Reedquist K. A., Druker B. J., Band H., D'Andrea A. D. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood. 89:1997;3166-3174.
110. Wakioka T., Sasaki A., Mitsui K., Yokouchi M., Inoue A., Komiya S., Yoshimura A. APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains, inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia. 13:1999;760-767.
111. Verdier F., Chretien S., Billat C., Gisselbrecht S., Lacombe C., Mayeux P. Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2. An alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation. J. Biol. Chem. 272:1997;26173-26178.
112. Lecoq-Lafon C., Verdier F., Fichelson S., Chretien S., Gisselbrecht S., Lacombe C., Mayeux P. Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase. Blood. 93:1999;2578-2585.
113. Wickrema A., Uddin S., Sharma A., Chen F., Alsayed Y., Ahmad S., Sawyer S. T., Krystal G., Yi T., Nishada K., Hibi M., Hirano T., Platanias L. C. Engagement of gab1 and gab2 in erythropoietin signaling. J. Biol. Chem. 274:1999;24469-24474.
114. Ravichandran K. S., Lorenz U., Shoelson S. E., Burakoff S. J. Interaction of Shc with Grb2 regulates association of Grb2 with mSOS. Mol. Cell. Biol. 15:1995;593-600.
115. Tilbrook P. A., Ingley E., Williams J. H., Hibbs M. L., Klinken S. P. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO J. 16:1997;1610-1619.
116. Mano H., Mano K., Tang B., Koehler M., Yi T., Gilbert D. J., Jenkins N. A., Copeland N. G., Ihle J. N. Expression of a novel form of Tec kinase in hematopoietic cells and mapping of the gene to chromosome 5 near Kit. Oncogene. 8:1993;417-424.
117. Scharenberg A. M., Kinet J. P. PtdIns-3,4,5-P3: A regulatory nexus between tyrosine kinases and sustained calcium signals. Cell. 94:1998;5-8.
118. Yamashita Y., Watanabe S., Miyazato A., Ohya Ki., Ikeda U., Shimada K., Komatsu N., Hatake K., Miura Y., Ozawa K., Mano H. Tec and Jak2 kinases cooperate to mediate cytokine-driven activation of c-fos transcription. Blood. 91:1998;1496-1507.
119. Li H. L., Davis W. W., Whiteman E. L., Birnbaum M. J., Pure E. The tyrosine kinases Syk and Lyn exert opposing effects on the activation of protein kinase Akt/PKB in B lymphocytes. Proc. Natl. Acad. Sci. USA. 96:1999;6890-6895.
120. Frearson J. A., Alexander D. R. The role of phosphotyrosine phosphatases in haematopoietic cell signal transduction. Bioessays. 19:1997;417-427.
121. Tsui H. W., Siminovitch K. A., de Souza L., Tsui F. W. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4:1993;124-129.
122. Bignon J. S., Siminovitch K. A. Identification of PTP1C mutation as the genetic defect in motheaten and viable motheaten mice: A step toward defining the roles of protein tyrosine phosphatases in the regulation of hemopoietic cell differentiation and function. Clin. Immunol. Immunopathol. 73:1994;168-179.
123. Yang W., Tabrizi M., Berrada K., Yi T. SHP-1 phosphatase C-terminus interacts with novel substrates p32/p30 during erythropoietin and interleukin-3 mitogenic responses. Blood. 91:1998;3746-3755.
124. Tang T. L., Freeman R. M. Jr., O'Reilly A. M., Neel B. G., Sokol S. Y. The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell. 80:1995;473-483.
125. Tauchi T., Feng G. S., Shen R., Hoatlin M., Bagby G. C. Jr., Kabat D., Lu L., Broxmeyer H. E. Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J. Biol. Chem. 270:1995;5631-5635.
126. Chin H., Saito T., Arai A., Yamamoto K., Kamiyama R., Miyasaka N., Miura O. Erythropoietin and IL-3 induce tyrosine phosphorylation of CrkL and its association with Shc, SHP-2, and Cbl in hematopoietic cells. Biochem. Biophys. Res. Commun. 239:1997;412-417.
127. Pluskey S., Wandless T. J., Walsh C. T., Shoelson S. E. Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J. Biol. Chem. 270:1995;2897-2900.
128. Qu C. K., Shi Z. Q., Shen R., Tsai F. Y., Orkin S. H., Feng G. S. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol. Cell. Biol. 17:1997;5499-5507.
129. Li Y., Davis K. L., Sytkowski A. J. Protein kinase C-epsilon is necessary for erythropoietin's up-regulation of c-myc and for factor-dependent DNA synthesis. Evidence for discrete signals for growth and differentiation. J. Biol. Chem. 271:1996;27025-27030.
130. Klingmuller U., Wu H., Hsiao J. G., Toker A., Duckworth B. C., Cantley L. C., Lodish H. F. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc. Natl. Acad. Sci. USA. 94:1997;3016-3021.
131. Helgason C. D., Damen J. E., Rosten P., Grewal R., Sorensen P., Chappel S. M., Borowski A., Jirik F., Krystal G., Humphries R. K. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:1998;1610-1620.
132. Gram H., Schmitz R., Zuber J. F., Baumann G. Identification of phosphopeptide ligands for the Src-homology 2 (SH2) domain of Grb2 by phage display. Eur. J. Biochem. 246:1997;633-637.
133. Wu H., Klingmuller U., Acurio A., Hsiao J. G., Lodish H. F. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc. Natl. Acad. Sci. USA. 94:1997;1806-1810.
134. Hanazono Y., Odai H., Sasaki K., Iwamatsu A., Yazaki Y., Hirai H. Proto-oncogene products Vav and c-Cbl are involved in the signal transduction through Grb2/Ash in hematopoietic cells. Acta Haematol. 95:1996;236-242.
135. Miura Y., Miura O., Ihle J. N., Aoki N. Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J. Biol. Chem. 269:1994;29962-29969.
136. Damen J. E., Liu L., Wakao H., Miyajima A., Rosten P., Jefferson A. B., Majerus P. W., Krosl J., Humphries R. K., Krystal G. The role of erythropoietin receptor tyrosine phosphorylation in erythropoietin-induced proliferation. Leukemia. 11:1997;423-425.
137. He T. C., Jiang N., Zhuang H., Wojchowski D. M. Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway. J. Biol. Chem. 270:1995;11055-11061.
138. Smit L., Borst J. The Cbl family of signal transduction molecules. Crit. Rev. Oncog. 8:1997;359-379.
139. Broome M. A., Galisteo M. L., Schlessinger J., Courtneidge S. A. The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases. Oncogene. 18:1999;2908-2912.
140. Oda A., Sawada K., Druker B. J., Ozaki K., Takano H., Koizumi K., Fukada Y., Handa M., Koike T., Ikeda Y. Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors. Blood. 92:1998;443-451.
141. Ozaki K., Oda A., Wakao H., Rhodes J., Druker B. J., Ishida A., Wakui M., Okamoto S., Morita K., Handa M., Komatsu N., Ohashi H., Miyajima A., Ikeda Y. Thrombopoietin induces association of Crkl with STAT5 but not STAT3 in human platelets. Blood. 92:1998;4652-4662.
142. Nichols G. L., Raines M. A., Vera J. C., Lacomis L., Tempst P., Golde D. W. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood. 84:1994;2912-2918.
143. Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A., Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A. APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis. Oncogene. 18:1999;759-767.
144. Gu H., Pratt J. C., Burakoff S. J., Neel B. G. Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol. Cell. 2:1998;729-740.
145. Silva M., Grillot D., Benito A., Richard C., Nunez G., Fernandez-Luna J. L. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 88:1996;1576-1582.
146. Quelle F. W., Wang J., Feng J., Wang D., Cleveland J. L., Ihle J. N., Zambetti G. P. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev. 12:1998;1099-1107.
147. Packham G., White E. L., Eischen C. M., Yang H., Parganas E., Ihle J. N., Grillot D. A., Zambetti G. P., Nunez G., Cleveland J. L. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev. 12:1998;2475-2487.
148. Gregory T., Yu C., Ma A., Orkin S. H., Blobel G. A., Weiss M. J. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood. 94:1999;87-96.
149. Gregoli P. A., Bondurant M. C. The roles of Bcl-X(L) and apopain in the control of erythropoiesis by erythropoietin. Blood. 90:1997;630-640.
150. Motoyama N., Wang F., Roth K. A., Sawa H., Nakayama K., Nakayama K., Negishi I., Senju S., Zhang Q., Fujii S. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science. 267:1995;1506-1510.
151. Veis D. J., Sorenson C. M., Shutter J. R., Korsmeyer S. J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 75:1993;229-240.
152. Seger R., Krebs E. G. The MAPK signaling cascade. FASEB J. 9:1995;726-735.
153. Paul A., Wilson S., Belsham C. M., Robinson C. J., Scott P. H., Gould G. W., Plevin R. Stress-activated protein kinases: Activation, regulation and function. Cell Signal. 9:1997;403-410.
154. Xia Z., Dickens M., Raingeaud J., Davis R. J., Greenberg M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
155. Nagata Y., Nishida E. Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3. Blood. 89:1997;2664-2669.
156. Foltz I. N., Schrader J. W. Activation of the stress-activated protein kinases by multiple hematopoietic growth factors with the exception of interleukin-4. Blood. 89:1997;3092-3096.
157. Nagata Y., Kiefer F., Watanabe T., Todokoro K. Activation of hematopoietic progenitor kinase-1 by erythropoietin. Blood. 93:1999;3347-3354.
158. Rausch O., Marshall C. J. Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation. J. Biol. Chem. 274:1999;4096-4105.
159. Nagata Y., Takahashi N., Davis R. J., Todokoro K. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood. 92:1998;1859-1869.
160. Shan R., Price J. O., Gaarde W. A., Monia B. P., Krantz S. B., Zhao Z. J. Distinct role of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin. Blood. 1999.
161. Chen Y. R., Meyer C. F., Tan T. H. Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in gamma radiation-induced apoptosis. J. Biol. Chem. 271:1996;631-634.
162. Angel P., Imagawa M., Chiu R., Stein B., Imbra R. J., Rahmsdorf H. J., Jonat C., Herrlich P., Karin M. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. 49:1987;729-739.
163. Bergelson S., Klingmuller U., Socolovsky M., Hsiao J. G., Lodish H. F. Tyrosine residues within the intracellular domain of the erythropoietin receptor mediate activation of AP-1 transcription factors. J. Biol. Chem. 273:1998;2396-2401.
164. Jacobs-Helber S. M., Wickrema A., Birrer M. J., Sawyer S. T. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol. Cell. Biol. 18:1998;3699-3707.
165. Yang E., Zha J., Jockel J., Boise L. H., Thompson C. B., Korsmeyer S. J. Bad, a heterodimeric partner for bcl-xl and bcl-2, displaces bax and promotes cell death. Cell. 80:1995;285-291.
166. Kelekar A., Chang B. S., Harlan J. E., Fesik S. W., Thompson C. B. Bad is a BH3 domain-containing protein that forms an inactivating dimer with bcl-xl. Mol. Cell. Biol. 17:1997;7040-7046.
167. Zha J., Harada H., Osipov K., Jockel J., Waksman G., Korsmeyer S. J. BH3 domain of Bad is required for heterodimerization with bcl-xl and pro-apoptotic activity. J. Biol. Chem. 272:1997;24101-24104.
168. Ottilie S., Diaz J. L., Horne W., Chang J., Wang Y., Wilson G., Chang S., Weeks S., Fritz L. C., Oltersdorf T. Dimerization properties of human Bad. Identification of a BH3 domain and analysis of its binding to mutant bcl-2 and bcl-xl proteins. J. Biol. Chem. 272:1997;30866-30872.
169. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not bcl-xl. Cell. 87:1996;619-628.
170. Del Paso L., Gonzalez-Garcia M., Page C., Herrera R., Nunez G. Interleukin-3-induced phosphorylation of Bad through the protein kinase Akt. Science. 278:1997;687-689.
171. Blume-Jensen P., Janknecht R., Hunter T. The kit receptor promotes cell survival via activation of PI-3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8:1998;779-782.
172. Harada H., Becknell B., Wilm M., Mann M., Huang L. J., Taylor S. S., Scott J. D., Korsmeyer S. J. Phosphorylation and inactivation of Bad by mitochondria-anchored protein kinase A. Mol. Cell. 3:1999;413-422.
173. Lewis J. L., Marley S. B., Blackett N. M., Szydlo R., Goldman J. M., Gordon M. Y. Interleukin-3 (IL-3), but not stem cell factor (SCF) increases self-renewal by human erythroid burst-forming units (BFU-E) in vitro. Cytokine. 10:1998;49-54.
174. Jubinsky P. T., Krijanovski O. I., Nathan D. G., Tavernier J., Sieff C. A. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 90:1997;1867-1873.
175. Broudy V. C. Stem cell factor and hematopoiesis. Blood. 90:1997;1345-1364.
176. Wu H., Klingmuller U., Besmer P., Lodish H. F. Interaction of the erythropoietin and stem-cell-factor receptors. Nature. 377:1995;242-246.
177. Jacobs-Helber S. M., Penta K., Sun Z., Lawson A., Sawyer S. T. Distinct signaling from stem cell factor and erythropoietin in HCD57 cells. J. Biol. Chem. 272:1997;6850-6853.
178. Broudy V. C., Lin N. L., Buhring H. J., Komatsu N., Kavangh T. J. Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer. Blood. 91:1998;898-906.
179. Muta K., Krantz S. B., Bondurant M. C., Dai C. H. Stem cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation. Blood. 86:1995;572-580.
180. Danilkovitch A., Leonard E. J. Kinases involved in MSP/RON signaling. J. Leukocyte Biol. 65:1999;345-348.
181. Persons D. A., Paulson R. F., Loyd M. R., Herley M. T., Bodner S. M., Bernstein A., Correll P. H., Ney P. A. Fv2 is a truncated form of the Stk/RON receptor tyrosine kinase. Nature Genet. 1999.
182. Ratajczak J., Zhang Q., Pertusini E., Wojczyk B. S., Wasik M. A., Ratajczak M. Z. The role of insulin (INS) and insulin like growth factor-1 (IGF-1) in regulating human erythropoiesis. Studies in vitro under serum free conditions - Comparison to other cytokines and growth factors. Leukemia. 12:1998;371-381.
183. Damen J. E., Krosl J., Morrison D., Pelech S., Krystal G. The hyperresponsiveness of cells expressing truncated erythropoietin receptors is contingent on insulin-like growth factor-1 in fetal calf serum. Blood. 92:1998;425-433.
184. Sokol L., Luhovy M., Guan Y., Prchal J. F., Semeza G. L., Prchal J. T. Primary familial polycythemia: A frameshift mutation in erythropoietin receptor gene and increased sensitivity of erythroid progenitors to Epo. Blood. 86:1995;15-22.
185. Kralovics R., Indrak K., Stopka T., Berman B. W., Prchal J. F., Prchal J. T. Two new Epo R mutations: Truncated EPO receptors are most frequently associated with primary familial and congenital polycythemia. Blood. 90:1997;2057-2061.
186. Furukawa T., Narita M., Sakuae M., Otsuka T., Kuroha T., Masuko M., Azegami T., Kishi K., Takahashi M., Utsumi J., Koike T., Aizawa Y. Primary familial polycythemia associated with a novel point mutation in erythropoietin receptor. Br. J. Haematol. 99:1997;222-227.
187. Arcasoy M. O., Degar B. A., Harris K. W., Forget B. G. Familial erythrocytosis associated with a short deletion in erythropoietin receptor gene. Blood. 89:1997;4628-4635.
188. Percy M. J., McMullin M. F., Roques A. W., Westwood N. B., Acharya J., Hughes A. E., Lappin T. R., Pearson T. C. Erythrocytosis due to a mutation in erythropoietin receptor gene. Br. J. Haematol. 100:1998;407-410.
189. Kralovics R., Sokol L., Prchal J. T. Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia. J. Clin. Invest. 102:1998;124-129.
190. Miller B. A., Barber D. L., Bell L. L., Beattie B. K., Zhang M. Y., Neel B. G., Yoakim M., Rothblum L. I., Cheung J. Y. Identification of the erythropoietin receptor domain required for calcium channel activation. J. Biol. Chem. 274:1999;20465-20472.
191. Mirza A. M., Correa P. N., Axelrad A. A. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. Blood. 86:1995;877-882.
192. Correa P. N., Eskinazi D., Axelrad A. A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: Studies in an improved serum-free medium. Blood. 83:1994;99-112.
193. Mirza A. M., Ezzat S., Axelrad A. A. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood. 89:1997;1862-1869.
194. Helman D., Sandowski Y., Cohen Y., Matsumoto A., Yoshimura A., Merchav S., Gertler A. Cytokine-inducible SH2 protein (CIS3) and JAK2 binding protein (JAB) abolish prolactin receptor-mediated STAT5 signaling. FEBS Lett. 441:1998;287-291.
195. Masuhara M., Sakamoto H., Matsumoto A., Suzuki R., Yasukawa H., Mitsui K., Wakioka T., Tanimura S., Sasaki A., Misawa H., Yokouchi M., Ohtsubo M., Yoshimura A. Cloning and characterization of novel CIS family genes. Biochem. Biophys. Res. Commun. 239:1997;439-446.
196. Endo T. A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., Matsumoto A., Tanimura S., Ohtsubo M., Misawa H., Miyazaki T., Leonor N., Taniguchi T., Fujita T., Kanakura Y., Komiya S., Yoshimura A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387:1997;921-924.
197. Yoshimura A. The CIS/JAB family: Novel negative regulators of JAK signaling pathways. Leukemia. 12:1998;1851-1857.